Leveraging Salmonella typhi Ty21a to activate innate and adaptive immune responses against cancer cells
Socium Therapeutics is developing an orally-administered cancer vaccine platform based on recombinant Salmonella typhi Ty21a, the same strain that has been used as the typhoid vaccine since 1989. Socium’s platform – CReST (Cross-presenting Recombinant Salmonella typhi Ty21a) – induces an innate immune response from Salmonella pathogenesis and an adaptive immune response by cross-presenting tumor-specific antigen to enhance activation of killer T-cells.

The SociumTeam

Socium’s leadership team and advisory board members have decades of experience in immunotherapy, vaccine development, translational research, clinical program implementation and intellectual property protection.

Timothy M. Salmon, JD

 

Timothy M. Salmon, JD

Co-founder, President & Chief Executive Officer


Robert G. Schaut, PhD

 

Robert G. Schaut, PhD

Immunologist


Daniel Mitry, JD

 

Daniel Mitry, JD

Co-founder, VP of Business Development

Debasish Roychowdhury, MD

 

Debasish Roychowdhury, MD

Advisory Board Member


Anna Ferrari, MD

 

Anna Ferrari, MD

Advisory Board Member


Professor Joachim Fensterle, PhD

 

Professor Joachim Fensterle, PhD

Advisory Board Member

Marcela F. Pasetti, PhD

 

Marcela F. Pasetti, PhD

Advisory Board Member


James E. Galen, PhD

 

James E. Galen, PhD

Advisory Board Member

News

Latest News

Contact

Get InTouch

Email:

info@sociumtherapeutics.com

Phone:

(973) 585-6202

Address:

90 E. Halsey Road
Suite 311
Parsippany, NJ 07054